Study Of SU011248 In Combination With Paclitaxel/Carboplatin In Patients With Advanced Solid Tumors

• Status: Completed
• Trial end date: 2009-02-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to test SU011248 (sunitinib) in combination with paclitaxel/carboplatin. This combination regimen will be tested for safety and antitumor activity.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Albumin-Bound Paclitaxel; Carboplatin; Paclitaxel; Sunitinib

Criteria

Inclusion Criteria:

• Histologically or cytologically proven diagnosis of any advanced solid malignancy that is not amenable to treatment with curative intent

• Candidates for treatment with carboplatin and paclitaxel with maximum of 2 prior chemotherapy regimens

• ECOG performance status 0 or 1

Exclusion Criteria:

• Prior chemotherapy, radiation therapy or surgery within 4 weeks prior to study entry except palliative radiotherapy to non-target, metastatic lesions

• Diagnosis of any second malignancy within the past 3 years